Skip to content

Depreciation at other companies

MBX Biosciences, Inc. logo
MBX Biosciences, Inc.MBX
Organon logo
OrganonOGN
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
Harmony Biosciences Holdings, Inc. logo
Harmony Biosciences Holdings, Inc.HRMY

Other financials

Income statement

See full
Revenue$80.1M+23.2%
Operating income-$6.6M+70.2%
Net income-$25.2M+37.7%
EPS (diluted)-$0.10+52.4%

Balance sheet

See full
Cash & equivalents$156.2M+36.2%
Total debt$155.2M+6.1%
Total equity-$307.9M+27.8%
Total assets$462.5M+42.7%

Cash flow

See full
Operating cash flow-$27.7M-22.5%
CapEx$189.0K
Free cash flow-$27.9M-23.3%

Valuation

See full
Market cap$811.73M+283%
Enterprise value$810.81M+233%
P/S1.9×+1.1×

Profitability

See full
Operating margin18.1%+12.7pp
Net margin-34.8%+8.0pp
FCF margin-30.7%

Returns & leverage

See full
Return on equity-260.8%
Debt / equity0.8×
Current ratio1.5×+0.4×

Where this comes from

Reported directly by Esperion Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Esperion Therapeutics's depreciation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Esperion Therapeutics's depreciation?
Esperion Therapeutics (ESPR) reported depreciation of $27K in Q1 2026.
How has Esperion Therapeutics's depreciation changed year-over-year?
Esperion Therapeutics's depreciation increased by 3.8% year-over-year, from $26K to $27K.
What is the long-term trend for Esperion Therapeutics's depreciation?
Over 4 years (2021 to 2025), Esperion Therapeutics's depreciation has grown at a -35.6% compound annual growth rate (CAGR), from $612K to $105K.